Beijing SL Pharmaceutical Co Ltd

The company's capital structure is characterized by a strong equity base, with total equity of CNY 5.18 billion and no long-term debt, resulting in a debt-to-equity ratio of 0.0. Liquidity is robust, as evidenced by a current ratio of 2.87, indicating the company has sufficient current assets to cover its current liabilities. However, the company reported negative operating income of CNY -279.28 million and a net loss of CNY -347.19 million, which raises concerns about its profitability and returns. The return on equity (ROE) is -6.7%, and the return on assets (ROA) is -5.72%, both significantly below the industry median for pharmaceutical companies. Profitability metrics are underperforming relative to industry norms. The company's gross profit of CNY 386.77 million represents a gross margin of 62.0%, which is in line with the industry median. However, the operating margin is -44.8%, and the net margin is -55.6%, both of which are well below the industry median for pharmaceutical firms. These figures suggest that the company is struggling with cost control and operational efficiency, which is a red flag for investors. Geographically, the company's revenue is concentrated in the domestic Chinese market, with no disclosed international operations. The company operates in a single business segment, which increases its exposure to local regulatory and economic risks. There is no indication of revenue diversification across product lines or geographic regions, which could limit its ability to weather market-specific downturns. The company's growth trajectory is mixed. Revenue for the latest period was CNY 623.64 million, but the company reported a net loss. Analysts have recorded a last actual revenue of CNY 1.12 billion, which is higher than the reported revenue, suggesting potential discrepancies or timing differences in reporting. The company's free cash flow is negative at CNY -392.29 million, driven by capital expenditures of CNY -192.97 million. This indicates that the company is investing in its operations but is not generating sufficient cash to cover these investments. Risk factors include the company's negative net income and operating income, which could impact its ability to service liabilities or fund future operations. The risk assessment indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative ROE and ROA suggest that it is not generating returns for shareholders, which could lead to pressure for strategic changes or cost-cutting measures. Recent events include the filing of financial results showing a net loss and negative operating income. There are no disclosed earnings call transcripts or recent regulatory filings that provide additional context on the company's performance. The ESG profile is mixed, with a low social pillar score of 18.86 and a governance score of 39.29, indicating potential governance and social responsibility concerns. The ESG controversies score is 100.00, suggesting no recent controversies.